Most venture capital firms wait for a founder to walk in with a pitch deck, decide whether to back it, and then get out of the way. W Health Ventures does something closer to the opposite: it identifies a healthcare gap first, spends over a year testing and de-risking the opportunity with its own in-house team, and only then recruits a founding team to actually run the company. That unusual “company creation” model just attracted enough investor confidence to close a ₹700 crore second fund — comfortably ahead of its original target, in a year when healthcare deal volumes in India have generally been harder to come by, not easier.
The Fund, in Numbers
W Health Ventures (WHV), a healthcare-focused venture capital firm operating out of Mumbai, Bengaluru, Delhi, and Boston, has closed its second fund at ₹700 crore (roughly $73 million), exceeding its initial target of ₹630 crore. That oversubscription is worth sitting with for a moment: Indian healthcare venture deal count reportedly fell from 78 to 54 between 2024 and 2025, and institutional capital in the space has generally been described as selective rather than freely available. Raising beyond target in that environment is a genuine vote of confidence, not a routine fundraising outcome.
Fund II has been registered as a Category II Alternative Investment Fund (AIF) with the Securities and Exchange Board of India (SEBI) — a shift from Fund I, which was based in the US. Limited partners in the new fund include family offices and institutions across both India and the US with a specific interest in Indian healthcare, according to the firm.
The capital will be deployed across 8 to 10 healthcare companies over a four-year investment period, with the firm targeting two to three new companies built per year. Typical investment ticket sizes range between ₹30 crore and ₹50 crore, concentrated on first-to-market, single-specialty healthcare solutions — a notably focused thesis compared to funds that spread bets across a broader, more generalist healthcare portfolio.
The “Company Creation” Model: What Actually Makes This Different
W Health Ventures’ central pitch is architectural, not just financial. Rather than functioning as a conventional venture fund that primarily selects among existing startups competing for capital, the firm builds companies from the idea stage using an in-house team of roughly 50 physicians, operators, and technologists. That team identifies specific, documented gaps in healthcare delivery, spends 12 to 18 months evaluating and de-risking the opportunity internally, and only then recruits a founding team to build the company around a problem that’s already been validated — rather than validating the problem alongside a founder who’s already committed to a specific solution.
Managing Partner Dr. Pankaj Jethwani framed the underlying thesis directly: “India is at an inflection point in healthcare as the rising demand and constrained supply create a structural mismatch. That mismatch is where lasting businesses are built. What keeps most people away isn’t the opportunity, it’s how hard healthcare is to build in. We think that is precisely where the value is.”
That’s a meaningfully different starting point than most venture capital theses, which generally treat market difficulty as a reason for caution. W Health Ventures is explicitly positioning healthcare’s structural difficulty — regulatory complexity, clinical risk, long sales cycles into hospital systems — as the actual source of defensibility and value, on the logic that difficulty which deters most investors also deters most competitors from building durable companies in the same space.
The Portfolio So Far: Everhope Oncology and Everbright Health
Fund II has already deployed capital into two companies, both illustrating the model in practice.
Everhope Oncology, founded in partnership with Narayana Health in March 2025, is focused on bringing more coordinated, patient-centred cancer care to India — a genuinely urgent gap given that India faces nearly 2 million new cancer cases annually, with incidence projected to double by 2045. Rather than building another multi-specialty hospital where an oncology department competes internally for limited oncologist time against cardiology, orthopaedics, and general medicine, Everhope’s model is built around dedicated oncology satellites — daycare chemotherapy centres and surgical oncology facilities located close to where patients actually live, backed by a 24/7 care concierge service supporting patients between treatment sessions. The company’s clinical board draws directly on Narayana Health’s protocols and network, while Everhope’s own team handles patient experience and care-coordination architecture. Everhope raised a $10 million “day-zero” investment led by Narayana Health, and has since gone on to back further growth — including a $2.8 million investment into Specialty Surgical Oncology Hospital, a Western India surgical cancer hospital chain, to expand its own specialised cancer care delivery.
Everbright Health, the fund’s second confirmed portfolio company, takes the India-built model in the opposite direction across the US-India corridor: it’s a US-based, tech-enabled mental health platform developing advanced interventions specifically for treatment-resistant depression — expanding access to treatment options for patients who haven’t responded to conventional approaches. Jethwani noted a third company built under Fund II is already in the pipeline, reinforcing the firm’s stated cadence of two to three new company launches per year.
Across its full portfolio — including earlier companies Elevate Now, Nivaan Care, and Hoola Health, built through Fund I — W Health Ventures states its companies have collectively reached more than 25 million patients to date.
The India-US Corridor Strategy
One structural detail worth understanding: W Health Ventures has been explicit that it doesn’t invest in companies lacking a genuine India-focused angle, even when building for the US market. Roughly two-thirds of the firm’s capital is allocated to companies domiciled in India and targeting the Indian market directly, with the remaining third reserved specifically for companies operating across the US-India healthcare corridor — Everbright Health being a clear example of that second category, built on the same company-creation infrastructure and clinical rigor the firm applies domestically, but addressing a US patient population.
This dual-market positioning is a distinctive bet: rather than treating India and the US as separate investment theses, W Health Ventures is using its India-based clinical and operational expertise as a foundation for building companies that can serve high-value healthcare gaps in both markets simultaneously — a model that, if it scales successfully, could offer Indian healthcare talent and operational infrastructure a genuine export pathway into US healthcare delivery, not just a domestic growth story.
Why This Fund Matters for Indian Healthcare and MedTech
W Health Ventures’ approach connects to a broader pattern taking shape across Indian healthcare investment: a shift from purely capital-driven venture funding toward what the firm and observers have described as a “venture studio” model — one where the fund itself absorbs the earliest, highest-risk stage of company building (problem validation, clinical protocol design, initial team assembly) before conventional startup risk even begins. In a sector where deal volumes have been softening and investors have grown more selective, an oversubscribed ₹700 crore raise for precisely this model suggests limited partners increasingly see structural, ground-up company building as a more reliable path to returns in Indian healthcare than backing pre-formed startups competing for the same conventional VC dollars.
What to Watch Next
The real test for W Health Ventures’ Fund II will be execution against its own stated cadence — two to three new companies launched per year, reaching 8 to 10 total portfolio companies within the four-year investment window — and whether Everhope Oncology and Everbright Health’s early traction translates into the kind of scaled, category-leading outcomes the firm’s thesis depends on. With a third company already confirmed to be in development, and a fund explicitly targeting first-to-market, single-specialty gaps in a healthcare system defined by exactly the kind of structural mismatch Jethwani described, W Health Ventures’ next moves will be a useful bellwether for whether India’s healthcare venture capital landscape is genuinely shifting toward this ground-up, company-creation model — or whether this remains a distinctive, single-firm strategy rather than an industry-wide trend.
References
- YourStory — W Health Ventures Closes Fund II at Rs 700 Cr (https://yourstory.com/2026/09/w-health-ventures-closes-fund-ii-at-rs-700-crore)
- Business Standard — W Health Ventures Closes Second Fund at ₹700 cr, Eyes Company Incubation (https://www.business-standard.com/companies/news/w-health-ventures-closes-second-fund-at-rs-700-cr-eyes-company-incubation-126090800098_1.html)
- Indian Startup News — Healthcare-Focused W Health Ventures Closes Rs 700 Crore Fund II (https://indianstartupnews.com/news/healthcare-focused-w-health-ventures-closes-rs-700-crore-fund-ii-to-invest-in-startups-12506132)
- Medical Buyer — W Health Ventures Closes Second Fund at ₹700cr (https://medicalbuyer.co.in/w-health-ventures-closes-second-fund-at-%E2%82%B9700cr/)
- Tech Times — W Health Ventures Closes $73M India Healthcare Studio Fund Oversubscribed (https://www.techtimes.com/articles/327007/20260908/w-health-ventures-closes-73m-india-healthcare-studio-fund-oversubscribed.htm)
- Indian Startup Times — W Health Ventures Closes Second Fund at Rs 700 Crore to Build Healthcare Companies (https://www.indianstartuptimes.com/news/w-health-ventures-closes-second-fund-at-rs-700-crore-to-build-healthcare-companies/)
- W Health Ventures — Fund II, Official Announcement (https://www.whealthventures.com/fund-ii/)
- CB Insights — Specialty Surgical Oncology Secures $2.8 Million from Everhope Oncology Platform (https://www.cbinsights.com/company/2070-health)
Note: This article reflects publicly available information as of September 2026. Fund deployment timelines, specific portfolio company valuations, and further Fund II investments beyond Everhope Oncology and Everbright Health were not fully disclosed publicly at the time of writing.